Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$0.43 USD
-0.03 (-7.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.45 +0.02 (4.58%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Athira Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 125 | 104 | 64 | 20 | 5 |
Income After Depreciation & Amortization | -125 | -104 | -64 | -20 | -5 |
Non-Operating Income | 8 | 8 | 9 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -118 | -96 | -55 | -20 | -5 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -118 | -96 | -55 | -20 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -118 | -96 | -55 | -20 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -126 | -104 | -63 | -19 | -5 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -125 | -104 | -64 | -20 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.02 | 37.73 | 36.92 | 11.97 | NA |
Diluted EPS Before Non-Recurring Items | -3.09 | -2.53 | -1.49 | -1.67 | NA |
Diluted Net EPS (GAAP) | -3.09 | -2.53 | -1.49 | -1.67 | -1.45 |
Fiscal Year end for Athira Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 28.02 | 27.69 | 30.64 | 35.04 | 31.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | -28.02 | -27.69 | -30.64 | -35.04 | -31.65 |
Non-Operating Income | 1.17 | 1.35 | 1.73 | 2.07 | 2.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -26.86 | -26.34 | -27.29 | -32.97 | -29.60 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -26.86 | -26.34 | -27.29 | -32.97 | -29.60 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -26.86 | -26.34 | -27.29 | -32.97 | -29.60 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 38.38 | 38.32 | 38.02 | 38.06 | 38.00 |
Diluted EPS Before Non-Recurring Items | -0.70 | -0.69 | -0.71 | -0.87 | -0.78 |
Diluted Net EPS (GAAP) | -0.70 | -0.69 | -0.71 | -0.87 | -0.78 |